Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock?

Merck (MRK) is strategically diversifying its portfolio ahead of its blockbuster cancer drug Keytruda's patent expiration in 2028, which currently accounts for approximately 50% of its pharmaceutical sales. This includes the recent $10 billion acquisition of Verona Pharma for its COPD drug Ohtuvayre, which generated $71.3 million in Q1 sales and grew 95% sequentially, alongside strong launches for new products like Capvaxive and Winrevair. While facing challenges such as declining Gardasil sales in China and potential Keytruda competition, Merck is aggressively expanding its pipeline, aiming for 20 new product launches, positioning it to mitigate future revenue gaps despite recent stock underperformance and declining EPS estimates.

Analysis

Merck is executing a multifaceted strategy to de-risk its portfolio ahead of the 2028 patent expiration of its blockbuster drug, Keytruda, which accounts for approximately 50% of its pharmaceutical sales. The cornerstone of this strategy is the $10 billion definitive agreement to acquire Verona Pharma, securing Ohtuvayre, a newly approved COPD treatment with a unique dual PDE3/PDE4 inhibition mechanism. Ohtuvayre's strong commercial start, with $71.3 million in first-quarter sales representing 95% sequential growth, signals significant potential. This M&A activity is complemented by robust internal pipeline development, which has nearly tripled its phase III assets since 2021, positioning Merck to launch around 20 new products. Notably, new launches like Capvaxive and Winrevair are already showing strong uptake. However, Merck faces considerable headwinds, including a temporary halt in shipments of its second-largest product, Gardasil, to China due to weak demand, and emerging competitive threats to Keytruda, such as Summit Therapeutics' ivonescimab. These challenges are reflected in the stock's 14.0% year-to-date decline and downward revisions to 2025 and 2026 EPS estimates. Despite the negative sentiment, the company's valuation appears attractive, with a forward P/E ratio of 8.99, well below the industry average of 15.16.

Key Decisions for Investors

• Despite near-term stock underperformance and negative estimate revisions, long-term investors should consider Merck's proactive strategy to mitigate the 2028 Keytruda patent cliff through strategic M&A and a fortified late-stage pipeline.
• Investors should closely monitor key risks, including the pace of Gardasil sales recovery in China and competitive data for Keytruda, particularly from potential rivals like Summit Therapeutics' ivonescimab.
• The current valuation, with a forward P/E of 8.99, may offer an attractive entry point for value-oriented investors who are confident in the commercial potential of new products like Ohtuvayre, Capvaxive, and Winrevair.
• Watch for the FDA's decision on the subcutaneous formulation of Keytruda, expected in September, as a key near-term catalyst that could significantly impact the drug's lifecycle and future revenue projections.